November 4, 2010
Preliminary data show an experimental therapeutic vaccine against hepatitis C virus boosted response rates by 12 percent compared with standard HCV treatment of ribavirin and pegylated interferon, researchers reported at the annual meeting of the American Association for the Study of Liver Diseases in Boston.
Paul Pokros, MD, of the Scripps Clinic in La Jolla, Calif., said the Phase II trial of 133 patients included those who were treatment-naive and those who had not responded to standard treatment. Results in both subgroups were similar to the overall outcome but did not reach statistical significance compared with standard treatment. However, the findings are enough to warrant continued development of GI-5005, a recombinant, inactivated yeast that expresses hepatitis antigens.
GI-5005 generated an immune response similar to that seen among patients who are able to clear HCV without medication -- a modest response to the viral envelope proteins and a robust response to the nonstructural proteins NS3 and NS5.
11.02.2010; Michael Smith
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|